ArticleJournal of thoracic disease2021

Pretreatment neutrophil-to-lymphocyte ratio as an important prognostic marker in stage III locally advanced non-small cell lung cancer: confirmatory results from the PROCLAIM phase III clinical trial.

Tithi Biswas et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.